European Companies Search Engine
EU funding (€784,470): Evaluation of a production ready portable, Point-of-Need Platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 … Hor1 Sept 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Evaluation of a production ready portable, Point-of-Need Platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection.
This project focuses on rapid (40min), simple, Point-of-Need COVID-19 testing, e.g. surgery/home (via first responders)/transit points of entry. BG Research (BGR) has developed direct from crude sample detection of viral pathogens – the QuRapID-XF technology, removing requirement for nucleic acid extraction, expert users or a laboratory; results delivered while you wait. Tests utilise the Gold Standard polymerase chain technology as current clinical reference tests, but using our novel reagent, directly breaking open the virus and a single enzyme system that is resistant to the inhibitory compounds found in crude biological samples. Objectives: 1. Develop a lyophilised assay for direct detection of SARS-CoV-2 from nasal swab samples. 1. Production scaling of a portable instrument for performing the test at Point-of-Need. 2. Demonstration of a pipeline for rapidly deploying new assays in response to future outbreaks and detection from a wider range of sample types. 3. Validation of the assay at 3 independent sites using clinical samples, generating data sets for regulatory approval. Achieving the objectives: BGR has pre-production portable systems in testing for the in-field detection of veterinary diseases from animal nasal swabs. This project will bring scaled production of the product forward by minimally 3 months together with a validated lyophilised SARS-CoV-2 assay. The team has proven experience in diagnostics design and development and will have access to clinical patient samples from Italy and France, generating quantified standards and performance evaluation data that BG Research will document under its ISO13485 quality standard and generate data for EUA regulatory approval. Relevance to Work P: The IMI2 call is seeking innovative diagnostics to have impact in combating the current Coronavirus outbreak and this proposal to provide rapid and simplified differential diagnostics at the point of need, is directly aligned with the scope.
Funded Companies:
| Company name | Funding amount |
| B G Research Ltd. | €28,750 |
| Biogene Ltd. | €0.00 |
| €246,250 | |
| Universite d'AIX Marseille | €321,750 |
| Universite de Corse Pascal Paoli | €187,720 |
Source: https://cordis.europa.eu/project/id/101005075
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "B G Research Ltd. - EU funding (€784,470): Evaluation of a production ready portable, Point-of-Need Platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
